AACI Association of American Cancer Institutes

PO Box 7317
Pittsburgh, PA 15213

www.aaci-cancer.org

DRIVING SOLUTIONS **TOGETHER**



AACI CRI
Clinical Research Innovation

17th Annual AACI CRI Meeting

June 23-25, 2025

Loews Chicago O'Hare Hotel • Rosemont, IL

AACI CRI 2025 Steering Committee

Chair: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Chair-elect: Margaret Kasner, MD, MSCE
Sidney Kimmel Comprehensive Cancer Center at Jefferson

Dina Aziz, MS
The University of Texas MD Anderson Cancer Center

Sarah Bigelow, CCRP
Tulane Cancer Center
Louisiana Cancer Research Center

Frances Brogan, MSN, RN, OCN, CCRP
Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

Angela Campbell, MS
The Ohio State University
Comprehensive Cancer Center – The James

Mario M. Contreraz, MBA, MSN, RN
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Arcadia Cruz, PhD
UC San Diego Moores Cancer Center

Angela Fritsche, MPA
Mayo Clinic Comprehensive Cancer Center

Muhammad Furqan, MBBS
Holden Comprehensive Cancer Center, University of Iowa

Edward J. Kim, MD, PhD
UC Davis Comprehensive Cancer Center

Wendy Law, PhD
Fred Hutch Cancer Center

Jay A. Lebsack, MA
Moffitt Cancer Center

Jennifer W. Pegher, MA, MBA
Association of American Cancer Institutes

Jennifer Rogers, MBA
UK Markey Cancer Center

Lauren Wall, MS
The University of Chicago Medicine Comprehensive Cancer Center

Meeting App and Social Media

The agenda, presentations, exhibitor information, and attendees list are available on the meeting app.

To access the app:

- **Download "Cvent Events" from your mobile app store.**
- **Within the Cvent Events app, search for "17th Annual AACI Clinical Research Innovation Meeting" and download the meeting.**
- **Log in with the name and email used during registration.**
- **You will receive a 6-digit verification code. Enter your code and log in.**

The meeting app can also be accessed on your desktop at:
https://cvent.me/drZD84

Presentations and session recordings can only be accessed using the desktop version of the app.

Bluesky: @aacicancer.bsky.social
Facebook/Instagram/Threads: @AACICancer
LinkedIn: @aaci-cancer
X: @AACI_Cancer
Hashtag: #CRI2025
Wireless Network: AACI CRI Wi-Fi
Password: aaci2025

AACI CRI Welcome

The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) program provides a forum for research leaders at AACI cancer centers to develop and share best practices for the efficient operation of clinical trials offices (CTOs).

The programming of the 17th Annual AACI CRI Meeting, "Driving Solutions Together," fosters opportunities for peer-to-peer networking and collaboration among cancer center members.

CRI Strategic Plan Goals and Projects

- Increase AACI cancer center member participation in CRI and integrate CRI into AACI programs and initiatives
- Collect and disseminate benchmarking data to develop and support cancer center clinical trials
- Encourage cancer centers to share emerging practices for improving community outreach and engagement in clinical trials
- Develop clinical research education, resources, and networks for professional development to continue fostering communication and mentoring opportunities
- Increase engagement with industry and other stakeholders to support CRI
- Develop financially sustainable models for facilitating efficient and rapid CTO operations

AACI CRI Meeting Objectives

- Learn how to optimize multi-site structures by exploring innovative strategies to improve the efficiency of treatment trials across cancer center locations and develop actionable solutions to overcome challenges
- Share insights from investigators, research teams, and stakeholders on effective strategies to streamline investigator-initiated trials and discuss funding mechanisms that support successful implementation
- Provide an overview of the new components of the National Cancer Institute Cancer Center Support Grant to understand the requirements needed for a successful application and hear updates about the Clinical Trials Reporting Program
- Discuss the evolving cancer center program and hear personal career stories to identify opportunities for shaping the next generation of oncology workers
- Facilitate networking and community building with like-minded professionals to build supportive relationships among AACI cancer center members and stakeholders
- Listen to industry leaders share their vision for advancing clinical trials and discuss networking and partnership opportunities to improve clinical trial accessibility and innovation

Who Attends This Meeting?

- Individuals from AACI member cancer centers, including:
  - CTO administrative directors, medical directors, managers, and supervisors
  - Deputy/associate directors of clinical research administration
  - Cancer center administrators
  - Research regulatory managers and staff
  - Clinical research finance directors, managers, and supervisors
  - Biostatisticians and informatics specialists
- AACI Sustaining Members
- AACI Corporate Roundtable members
- Representatives from industry, including drug development companies, clinical research organizations, and consultants
- Information technology companies that support cancer center clinical research management
- Like-minded organizations promoting patient access to clinical trials

MEETING PROGRAM

17th Annual AACI Clinical Research Innovation (CRI) Meeting

Driving Solutions Together

Monday, June 23 – Wednesday, June 25 • Loews Chicago O'Hare Hotel, Rosemont, IL

All sessions are in central time. Sessions are held in Cassatt Ballroom unless otherwise noted.

Monday, June 23

10:00 AM **Registration Opens** *Artist Foyer*

11:00 AM **Exhibits Open** *Artist Foyer*

12:15 PM **Welcome**

Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

12:30 PM **Keynote | Becoming the Story, Not a Statistic**
With support from Advarra

Latina patient and two-time cancer survivor Loriana Hernández-Aldama shares her journey through clinical trials. Having faced systemic blind spots, broken trust, and underrepresentation, she challenges the audience to see beyond the data. Her message is a reminder that every data point has a face, a family, and a future – and that those behind the trials have the power to move not just science, but lives, forward.

Moderator: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Loriana Hernández-Aldama
ArmorUp for Life

1:30 PM **Seeking Clarity for the CCSG and Beyond**

As the restructuring of the National Cancer Institute and Cancer Center Support Grant (CCSG) submission and review processes continues, cancer centers are seeking guidance. Colleagues from cancer centers that have recently completed their CCSG site visits and renewals will share how they prepared amid uncertainty, including strategies they employed to improve metrics.

Moderator: Jennifer Rogers, PhD
UK Markey Cancer Center

Angela Campbell, MS
The Ohio State University Comprehensive Cancer Center – The James

Collette Houston
Memorial Sloan Kettering Cancer Center

Teena Kochukoshy, MD, MS
Fox Chase Cancer Center, Temple Health

2:30 PM **Networking Break**

3:00 PM **Shaping the Future: Empowering Career Pathways in Oncology**

Discover how cancer center leaders are shaping broad and successful career paths as they prepare the next generation of the oncology workforce. Presenters will discuss their personal career journeys and offer practical insights into mentorship, training, and structural changes that are expanding opportunities in the workforce.

Moderator: Lauren Wall, MS
The University of Chicago Medicine Comprehensive Cancer Center

Stefanie Belanger, MHA, CCRP
Duke Cancer Institute

Whitney Cunningham, MS, PHR
UK Markey Cancer Center

Danielle S. Mitchell
Black Women in Clinical Research

4:00 PM **Poster Session** *Avedon Ballroom*

5:30 PM **Welcome Reception** *Artist Foyer*
With support from Novartis

Tuesday, June 24

7:00 AM **General Breakfast** *Avedon Ballroom*

7:00 AM **CTO Administrative Directors Breakfast** *(invitation only)*
Prado Room

7:00 AM **CTO Medical Directors Breakfast** *(invitation only)*
Metropolitan Room

8:00 AM **Exhibits Open** *Artist Foyer*

8:15 AM **Welcome: State of the Union**

Moderator: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

8:30 AM **Keynote | The Key to Unlocking Effective Communications**

Listening to patients and colleagues and understanding and validating their perspectives are vital interpersonal skills, especially for oncology professionals tasked with compassionately and transparently delivering difficult news. Discussion will include strategies and real-world applications for navigating tough conversations, de-escalating with empathy, connecting with remote and hybrid workers, and creating a culture of meaningful feedback.

Moderator: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Chad Fritsche
Mayo Clinic Comprehensive Cancer Center

9:30 AM **Hub and Spoke: Running Clinical Trials at Multiple Sites**

Using a “hub and spoke” model can help cancer centers manage multi-site operations effectively. Panelists will highlight organizations that excel in treatment trials across locations and address key financial and budgeting strategies essential for sustaining multi-site structures. Leaders in cancer center operations, pharmacy, finance, and community oncology will also share practical insights on multi-site trials.

Moderator: Angela Fritsche, MPA
Mayo Clinic Comprehensive Cancer Center

Thomas Ferencz, RPh, BCOP
Yale Cancer Center, Yale School of Medicine

Jessica Moehle, CCRP
Huntsman Cancer Institute at the University of Utah

Sara Raboin, PhD
Yale Cancer Center, Yale School of Medicine

Aashka Shah, MHA
Memorial Sloan Kettering Cancer Center

10:30 AM **Break**

10:45 AM **Breakout Sessions**

Continuing the Conversation: Optimizing Multi-Site Structures in Cancer Centers

Louvre 1

Picking up where the general meeting left off, attendees will deepen their exploration of strategies to help cancer centers effectively manage multi-site operations. They will discuss challenges and solutions for coordinating treatment trials across multiple locations.

Financial Management in Clinical Trials

Louvre 3

Attendees will discuss common challenges in trial budgeting and billing compliance; identify ways to enhance financial oversight; share best practices for determining billable items, and more.

Inside the CCSG

Cassatt Ballroom

Cancer center leaders who have recently submitted applications for the National Cancer Institute's Cancer Center Support Grant (CCSG) will share tips and tricks for navigating this constantly changing process. Moderators and participants will share their own experiences, discuss preparation for site visits, and conduct a deep dive into specific reporting sections of the CCSG.

Managing Amendments in Clinical Trials

Guggenheim 1

Participants will explore the complexities of identifying, addressing, and implementing changes to clinical trials while minimizing disruptions to ongoing trials. They will also delve into the financial implications of amendments on the clinical trials office.

Part 1: Pre-Activation Strategies for Investigator-Initiated Trials

Warhol

Part 1 of a three-part series will concentrate on the pre-activation phase of investigator-initiated trials. Attendees will discuss strategies for developing robust study protocols, securing necessary funding, assembling effective research teams, and engaging stakeholders early in the process.

Sustaining Oversight: PRMC & DSMC in Clinical Trials

Guggenheim 2

Attendees will explore key aspects of Protocol Review and Monitoring Committees (PRMC) and Data and Safety Monitoring Committees (DSMC). They will engage in peer discussions on topics that are critical to ensuring patient safety, scientific integrity, and regulatory compliance, and will gain actionable insights to enhance their institution's oversight processes and optimize clinical trials.

Trial Activation Success

Louvre 2

Panelists will discuss critical components of trial activation, focusing on budgeting, contracting, and patient recruitment. They will share tools and resources that can streamline the activation process, enhance operational efficiency, and facilitate communication among stakeholders, and describe innovative approaches to patient recruitment through technology and community engagement.

11:45 AM **Lunch** *Avedon Ballroom*

1:15 PM

Navigating Investigator-Initiated Trials: Communication, Funding, and Operational Solutions

Managing investigator-initiated trials requires clear communication of research goals, efficient funding strategies, and strong operational support. Focusing on principal investigators, operational teams, and financial managers, this discussion will explore how to secure study funding, streamline protocol management, and identify who can assist in protocol and grant writing. It will also cover managing sponsor expectations and optimizing patient enrollment through collaborations with Community Outreach and Engagement offices.

Moderator: Margaret Kasner, MD, MSCE
Sidney Kimmel Comprehensive Cancer Center at Jefferson

Allison Camp, PhD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

David DeRemer, PharmD, FCCP, BCOP
University of Florida Health Cancer Center

John Hays, MD, PhD
The Ohio State University Comprehensive Cancer Center – The James

Kelly Kyle
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

Bhuvana Ramachandran, MS, MBA, MPH
Stanford Cancer Institute

2:15 PM Breakout Sessions

Advancing Education, Training, and Career Growth
Cassatt Ballroom

Attendees will explore strategies for enhancing education, training, and career development within clinical trials offices. Discussion topics include workforce challenges, mentorship programs, and professional advancement. Attendees will return to their cancer centers with practical tools and strategies to apply to their own career paths.

Continuing the Conversation: Optimizing Multi-Site Structures in Cancer Centers
Louvre 1

Picking up where the general meeting left off, attendees will deepen their exploration of strategies to help cancer centers effectively manage multi-site operations. They will discuss challenges and solutions for coordinating treatment trials across multiple locations.

Part 2: Navigating the Activation for Investigator-Initiated Trials
Warhol

Part 2 of a three-part series on investigator-initiated trials (IITs) will focus on the activation phase of IITs, highlighting the challenges and opportunities that arise during this critical period. Attendees will also discuss common activation issues, ensuring compliance, and site readiness.

Quality Assurance in Clinical Research
Louvre 3

Participants will discuss common quality assurance (QA) challenges and solutions. Topics include standard operating practices, tools for effective risk assessment, methods for identifying discrepancies, and strategies for continuous improvement. Through interactive exercises, attendees will share experiences, gain new insights, and brainstorm approaches to elevate QA processes.

Trial Activation Success
Louvre 2

Panelists will discuss critical components of trial activation, focusing on budgeting, contracting, and patient recruitment. They will share tools and resources that can streamline the activation process, enhance operational efficiency, and facilitate communication among stakeholders, and describe innovative approaches to patient recruitment through technology and community engagement.

Understanding the NCI Clinical Trials Reporting Program
Guggenheim 2

Moderators will lead a discussion on the National Cancer Institute (NCI) Clinical Trials Reporting Program, with participants sharing their reporting challenges and strategies for overcoming them.

Utilizing AI and Informatics in Cancer Research
Guggenheim 1

Delving into the transformative role of informatics and artificial intelligence (AI) in cancer clinical trials, attendees will learn how data-driven approaches can streamline trial design, improve patient selection, and optimize trial operations.

3:15 PM Networking and Dessert Break *Artist Foyer*

3:45 PM 2025 CRI Abstract Presentations

Abstracts received from AACI cancer center members focus on oncology research that illuminates clinical research challenges and solutions, accelerating cancer drug development. The CRI steering committee has selected three abstracts for presentation at this year's meeting. The abstract presentations will be followed by a Q&A session.

Moderator: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Kristina Humphries, MS, CCRC
The Ohio State University Comprehensive Cancer Center – The James

J. Kaitlin Morrison, PhD
UNC Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Lauren Wall, MS
The University of Chicago Medicine Comprehensive Cancer Center

8:00 PM Sip and Socialize

With support from Paradigm Health
Ice Bar, Lobby Level

Wednesday, June 25

7:00 AM **Breakfast** *Avedon Ballroom*

8:00 AM **Exhibits Open** *Artist Foyer*

8:00 AM **Navigating the Clinical Research Journey: Financial Support and Biospecimen Innovation Through Collaboration**

Attendees will learn about two initiatives aimed at improving the clinical research experience for both patients and research staff: the Equitable Access to Clinical Trials (EACT) project, which helps clinical trial participants achieve financial neutrality, and the Biospecimen Management Consortium, which is redesigning the biospecimen infrastructure. They will also discover new tools to support clinical trial participants and opportunities for collaboration.

Kira Pavlik, MPH, CCRP
Yale Cancer Center, Yale School of Medicine

8:15 AM **Strategic Portfolio Management in Clinical Trials: Metrics, Reporting, and Financial Oversight**

This session will focus on portfolio management, fiscal accountability, and aligning expectations for the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG). Panelists will share strategies for creating a balanced clinical trial portfolio and tracking performance metrics to meet reporting standards for the CCSG. Attendees will gain insights into methodologies for compiling, analyzing, and delivering trial data, including the use of tools like principal investigator scoreboards.

Moderator: Sarah Bigelow, CCRP
Tulane Cancer Center, Louisiana Cancer Research Center

Nicholas Fisher, MBA
Siteman Cancer Center

Aaron Gerds, MD, MS
Cleveland Clinic Cancer Center

Molly Gosky
UK Markey Cancer Center

Mili Ugrenovic-Petrovic, MS, CCRP
Moffitt Cancer Center

Katie M. Van Abel, MD
Mayo Clinic Comprehensive Cancer Center

9:15 AM **Breakout Sessions**

Continuing the Conversation: Optimizing Multi-Site Structures in Cancer Centers
Louvre 1
Picking up where the general meeting left off, attendees will deepen their exploration of strategies to help cancer centers effectively manage multi-site operations. They will discuss challenges and solutions for coordinating treatment trials across multiple locations.

Financial Management in Clinical Trials
Louvre 3
Attendees will discuss common challenges in trial budgeting and billing compliance; identify ways to enhance financial oversight; share best practices for determining billable items, and more.

Inside the CCSG
Cassatt Ballroom
Cancer center leaders who have recently submitted applications for the National Cancer Institute's Cancer Center Support Grant (CCSG) will share tips and tricks for navigating this constantly changing process. Moderators and participants will share their own experiences, discuss preparation for site visits, and conduct a deep dive into specific reporting sections of the CCSG.

Managing Amendments in Clinical Trials
Guggenheim 2
Participants will explore the complexities of identifying, addressing, and implementing changes to clinical trials while minimizing disruptions to ongoing trials. They will also delve into the financial implications of amendments on the clinical trials office.

Part 3: Post-Activation for Investigator-Initiated Trials
Warhol
Part 3, the final session of the investigator-initiated trials (IITs) breakout series, will address the post-activation phase. The discussion will include strategies for monitoring trial progress, managing data integrity, and ensuring successful study execution. Attendees will explore effective approaches for maximizing the impact of IITs beyond activation.

Trial Activation Success
Louvre 2
Panelists will discuss critical components of trial activation, focusing on budgeting, contracting, and patient recruitment. Tools and resources that can streamline the activation process, enhance operational efficiency, and facilitate communication among stakeholders will also be examined, along with innovative approaches to patient recruitment, including leveraging technology and community engagement.

9:15 AM **Breakout Sessions** *continued*

Utilizing AI and Informatics in Cancer Research
Cassatt Ballroom
Delving into the transformative role of informatics and artificial intelligence (AI) in cancer clinical trials, attendees will learn how data-driven approaches can streamline trial design, improve patient selection, and optimize trial operations.

10:15 AM **Break**

10:30 AM **Industry and Cancer Centers: Crafting Solutions Together** *With support from BeOne*

Panelists representing four AACI Corporate Roundtable members will share their vision for advancing clinical trials. They will explore topics including decentralized trials, expanding trial eligibility, stipends, and reimbursements. Attendees will have the opportunity to engage directly with industry leaders and learn how partnerships drive innovation and improve trial accessibility.

Moderator: Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Adam Kinsey
Merck

Dan Otap, CCRP
Genentech

Reneé Smith
J&J

Suellyn Sorensen
Lilly

11:30 AM **Closing Remarks**

Thomas J. George, Jr., MD, FACP, FASCO
University of Florida Health Cancer Center

Margaret Kasner, MD, MSCE
Sidney Kimmel Comprehensive Cancer Center at Jefferson

11:45 AM **Adjourn**

AACI CRI Meeting 2025 Abstracts

Abstracts are organized by category and completion status, then in alphabetical order by cancer center.

CATEGORIES:

Clinical Trial Operations
Community Outreach and Engagement & Health Equity
Cross-Cutting Innovation and Collaboration
Emerging Technology
Prioritization and Scientific Review
Training, Career Development, and Staff Retention

FIRST PLACE:
Improving Data Timeliness by Developing a CTO Process and Shifting Cultural Expectations
K. Humphries, C. Schweitzer, M. Wyse Bernard, J. Paskett, A. Campbell
The Ohio State University Comprehensive Cancer Center – The James

SECOND PLACE:
Hybrid Operations to Promote Equity (HOPE) - Bringing Trials Closer to Patients
K. Morrison, J. Potter, E. Moore, S. Wheeler, B. Martin, C. Lee
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

THIRD PLACE:
Measuring the Impact of Multiple Strategies to Increase Enrollment in Molecular Targeted Trials
L. Wall, V. Seseri, K. Kipping-Johnson, K. Cabrera, A. Larkin, S. Moellering
The University of Chicago Medicine Comprehensive Cancer Center

Clinical Trial Operations

1. **Enhancing Efficiency With a Comprehensive Site Information Packet**
   K. Kircher, J. Laeng, M. Kane, K. Gardner, H. Keaney, N. Rosas
   Cleveland Clinic Cancer Center

2. **Streamlining Clinical Trial Start-Up: Reducing Time to Open and Personnel Effort Through the TIME Trial Program**
   B. Eble, H. Keaney, J. Tomer
   Cleveland Clinic Cancer Center

3. **Targeted Review of Standard Operating Procedures for Enhanced Efficiency and Compliance**
   B. Daniels, S. Achberger
   Cleveland Clinic Cancer Center

4. **Utilizing OnCore Annotation Tab to Track Regulatory Team Acuity: A Workload Assessment Tool**
   V. Williams, C. Beard, B. Hicks
   Indiana University Melvin and Bren Simon Comprehensive Cancer Center

2025 Abstracts

5. **Hindsight is Always 20/20**
   J. Dominello, H. Cressman, C. Zuccaro, C. Galasso, E. Cunningham
   Karmanos Cancer Institute, Wayne State University

6. **Strategies for Expansion and Efficiency of Biospecimen Management for Multisite Investigator-Initiated Trials (IITs)**
   K. Weren, F. Hsu, P. Perez, A. Joshi, B. Pothuri
   Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

7. **The Critical Role of Pre-Planning at Site Selection: Ensuring Adequate Resources and Preventing Activation Delays**
   N. Catti, A. Joshi, M. Huber, K. Kallas
   Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

8. **Cancer Center Provider Onboarding: A Streamlined Approach**
   A. Tavlarides, A. Morey, K. Croghan, S. Blood, C. Van Oort, M. Perizzo, A. Fritsche
   Mayo Clinic Comprehensive Cancer Center

9. **Cancer-Related Clinical Trials Reporting Compliance in a Matrixed Cancer Center**
   B. Bachman, L. Winkowski, A. Youssef, J. Zbacnik, R. Hardtke, G. Nowakowski, K. Van Abel, A. Mansfield, A. Fritsche
   Mayo Clinic Comprehensive Cancer Center

10. **Broadening Representation on Institutional Research Committees – A Paradigm to Model**
    S. Hanley, R. Cambria, A. Rodavitch, C. Houston, D. Rathkopf, T. Kaley, R. Tuttle, E. O'Reilly, P. Sabbatini
    Memorial Sloan Kettering Cancer Center

11. **Can You Put a Dollar Value on NCI-Funded Research?**
    M. Warren, J. Mohr, L. Gaffney, J. Klinger, C. Houston, C. Aghajanian, P. Sabbatini
    Memorial Sloan Kettering Cancer Center

12. **Creation of the Pediatric Data & Safety Monitoring Committee: Providing Pediatric Expertise and Independent Oversight for MSK-Sponsored Pediatric Studies**
    D. Diaz-Leyton, X. Lekperic, K. Napolitano, C. Kolenut, S. Hanley, A. Rodavitch, C. Houston, B. Widemann, J. Bender
    Memorial Sloan Kettering Cancer Center

13. **Evolution of MSK's NCI Network Program**
    J. Mohr, L. Gaffney, M. Warren, C. Aghajanian, E. Zambrano-Acosta, J. Balletti, W. Blouin, C. Houston, A. Rodavitch, K. Yataghene, P. Sabbatini
    Memorial Sloan Kettering Cancer Center

14. **Using a Standardized Communication Document for Nursing in Clinical Trials to Improve Patient Care**
    A. Yang, A. Shi, M. Pilloff, A. Borrell, J. Pindulic, C. Motzkin, C. Delgado, H. Pacheco, M. Buckley, L. Klempner, J. Kim-Chang, R. Panchal, J. Lengfellner, N. Cimaglia, S. Terzulli, A. Drilon, P. Sabbatini
    Memorial Sloan Kettering Cancer Center

15. **Zero Accruals, Zero Delays: A Monthly Performance Monitoring Approach**
    C. Zamore, X. Lekperic, K. Napolitano, S. Hanley, C. Kolenut, A. Rodavitch, C. Houston, D. Rathkopf
    Memorial Sloan Kettering Cancer Center

16. **Amendments Post-Activation**
    N. Ugrenovic, M. Davis, J. Lebsack
    Moffitt Cancer Center

17. **Implementing a Non-Therapeutic Activation Team at a Comprehensive Cancer Center**
    A. Hoehn, N. Naas
    Moffitt Cancer Center

18. **On Ramp System: A Trailblazing Enhancement for Accelerating Clinical Trial Activation and Scaling Capacity**
    A. Voorhees, M. Ugrenovic, E. Royster, M. Davis, H. Anderson, V. Beland, J. Lebsack, E. Haura
    Moffitt Cancer Center

19. **The Power of Project Management Technology in Transforming Trial Activation Operations and Reporting**
    A. Voorhees, T. Lannon, M. Davis, R. McKinney, T. Ackerman, E. Scott, C. Conner
    Moffitt Cancer Center

20. **Implementing a Metrics-Based and Automated Approach to Clinical Trial Audit Prioritization**
    M. Hayes, M. Wanchoo, D. Castro, C. Burgin
    OHSU Knight Cancer Institute

21. **Advancing Clinical Research in Cell Therapy Trials: the Role of Centralized Operations at Princess Margaret Cancer Centre**
    K. Tung, P. Merante, M. Flynn-Post, S. Chan, H. Cole, S. Sellmann
    Princess Margaret Cancer Centre, University Health Network

22. **Improving Data Timeliness by Developing a CTO Process and Shifting Cultural Expectations**
    K. Humphries, C. Schweitzer, M. Wyse, J. Paskett, A. Campbell
    The Ohio State University Comprehensive Cancer Center – The James

23. **Streamlining Audit Preparation: Centralizing Audit Coordination Efforts Under the Quality Assurance Team**
    K. Dodds, J. Zvosec
    The Ohio State University Comprehensive Cancer Center – The James

24. **The Impact of Feasibility Tools on Study Start-up and Activation Timeline**
    D. Delbeau-Zagelbaum, R. Unawane, I. Chen, E. Sepiashvili, T. Miller, R. Knecht
    The Tisch Cancer Institute at Mount Sinai

2025 Abstracts

25. Operationalizing CTSU's Protocol and CIRB Update Listing for Processing Local Regulatory Documents
E. Arnold, J. Rarden, A. Willingham
The University of Kansas Cancer Center

26. Using SQL to Streamline Monthly Accrual Reporting
I. Nzuki, N. Karanja-Meek, D. Keusch, E. Eells, M. Willer
The University of Kansas Cancer Center

27. Implementation of a Centralized Clinical Trial Activation Unit Leads to Significant Reduction in Time to Activation at an NCI-Designated Cancer Center
J. Appelt, J. Molina, N. Johal, A. Malko, J. Warbrick, R. McKay, R. Eskander, J. Tull
UC San Diego Moores Cancer Center

28. From Idea to Impact: Developing the Research Science Liaison Position at Lineberger Comprehensive Cancer Center
K. Ashcraft, K. Quinn, A. Camp, L. Kiefer, J. Zeidner, K. Morrison
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

29. Taking Data Validation to the Next Level: Automating Data Validation Using CDASH-Standardized Global eCRFs – Phase II
S. Rachuri, K. Douglas, L. Barry, J. Tewell, A. Patwardhan, R. Johnson, T. Carroll, R. Gattas, K. Kennedy, S. Balu, K. Morrison, E. Crecelius
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

30. Unlocking Success in the Industry-Sponsored Trial Portfolio: The Impact of a Solid Tumor Research Science Liaison Position
K. Ashcraft, K. Quinn, A. Camp, L. Kiefer, K. Morrison
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

31. Streamlining Clinical Trial Cost Recovery: Enhancing Invoicing Accuracy and Collaboration at the UFHCC
K. Calbert, E. Monari, D. Veal, L. Marshall, L. Brown, A. Ivey, W. Brown-Porter, T. George
University of Florida Health Cancer Center

32. Efficient Temperature Report Generation Using an Application Programming Interface
J. Jang, D. Chan
University of Illinois Cancer Center

33. Commercial vs. Internal IRBs: Regulatory Burden of IRB Submissions, Three Years In
E. Sibilsky Enselman, J. Humfleet, D. Bashllari
University of Michigan Rogel Cancer Center

34. How to Successfully Open a New Medical Center to Clinical Research
C. Wilschke, J. Collins
University of Wisconsin Carbone Cancer Center

35. Implementation of a Coordinating Center for Multisite Investigator-Initiated Trials at Cedars-Sinai Cancer: Project Review, Key Insights, and Future-Proofing
D. Ngo, A. Tan, E. Hautamaki, P. Chang, M. Malikowski
Cedars-Sinai Cancer

36. Visibility is Vital: Utilizing Project Management Tools to Track Timelines and Metrics
M. Chaganti, P. Chang, W. Price, M. Sturgess, M. Malikowski
Cedars-Sinai Cancer

37. Clinical Research Processes: Monitoring the Process, Not Just the Outcome to Ensure Compliance
M. d'Aliberti, S. Achberger
Cleveland Clinic Cancer Center

38. Proactive Protection: The Impact of Systemic Quality Assurance Reviews on Reducing Major Audit Findings in Cooperative Group Research Studies
B. Brownrigg, S. Coakley, S. Achberger
Cleveland Clinic Cancer Center

39. Quarterly Quality Assurance Reviews to Help Reduce Major Findings for IND-Exempt Investigator-Initiated Trials
A. Barner-Martinez, S. Achberger
Cleveland Clinic Cancer Center

40. Refining IRB Submissions: Reducing Returns and Accelerating Approval Timelines
K. Kirchner, K. Gardner, H. Keaney, J. Laeng, N. Rosas
Cleveland Clinic Cancer Center

41. Streamlining Minimal Risk Studies: Creating a Request Process, Comprehensive Database, and Governance Structure
J. Laeng, B. Matia, M. Rump
Cleveland Clinic Cancer Center

42. Managing Study Amendments – Piloting a Centralized Approach
G. Subramanian, H. Loesch
Fred Hutch Cancer Center

43. The Catch 22 of Becoming a Useful Resource; Lessons Learn(ing)ed by the LCCC Consortium Investigator-Initiated Trials Office
K. Bouker, S. Shreeves, J. Zenreich, M. Mavredes
Georgetown Lombardi Comprehensive Cancer Center

44. Decentralized Clinical Trials Initiatives: Redesigning Clinical Trials to Minimize Patient and Site Burden
J. Moehle, J. Lengfellner, A. Shah
Huntsman Cancer Institute at the University of Utah; Memorial Sloan Kettering Cancer Center

45. Implementation of a Standardized Query Form Using OnCore for Monitoring and Auditing Investigator Initiated Trials (IITs)
H. Özkal, E. Bethscott, K. Thorne
Huntsman Cancer Institute at the University of Utah

46. Improving Clinical Trial Audit Effectiveness Through Comprehensive Reviews
E. Measom, E. Bethscott, K. Thorne
Huntsman Cancer Institute at the University of Utah

2025 Abstracts

47. Enhancing Clinical Trial Activation: Evaluating the Role of a Trial Activation Specialist
L. Sego, G. Lander, L. Rohn
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

48. Initiation and Innovations of Cellular Therapy Research in Multicenter Investigator-Initiated Trials
A. Bauchle, J. Kline
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

49. Streamlining Compliance: Implementing Advarra eReg for Clinical Trial Efficiency
L. Rohn, V. Williams, F. Kerr
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

50. Understanding Challenges in Clinical Research at the VA: Strengthening Collaboration in Clinical Research for Sustainable Growth
C. Nelson, L. Haney, S. Jalal, M. Sears, J. Spittler
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

51. Enhancing Efficiency and Advancing Cellular Therapy Research: Establishing a Dedicated Transplant and Cellular Therapy Program
B. Bodin, A. Joshi, K. Pickens, B. Pothuri, J. Mehnert
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

52. Mail to MyChart: Modernizing Dear Patient Letter Delivery in Clinical Trials
P. Warren, B. McGough, T. Imtiaz, E. Yepes, M. Dureja, A. Mesidor, R. Keller, S. Griglun, C. Infantino, H. He, J. Shirian, N. Catti, M. Huber, A. Joshi, Z. Asif, B. Pothuri, J. Mehnert
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

53. Shorter Activation Timelines Are Associated With Improved Enrollment Efficiency
K. Kallas, N. Catti, B. Pothuri, J. Mehnert
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

54. Clinical Trial Operation Turbo Speed – Progress & Opportunities to Decrease Study Start-up Timelines
K. Arends, L. Selnes-Brown, A. Denney, R. Nicklow, L. Ward, M. Schroeder, M. Tekman, S. Veum, L. Vose, J. Wurth, M. Johnson, A. Steevens
Masonic Cancer Center, University of Minnesota

55. Collaborative Synergy: Building a Multidisciplinary Team for Digital Protocol Implementation
T. Galloway, U. Sener, E. Breutzman, R. Anderson, K. Nesmith, K. Paulson, J. Gundelach, B. Kottschade, T. Haddad
Mayo Clinic Comprehensive Cancer Center

56. Florida Clinical Research Audit Preparation and Quality Process
A. Young, D. Haley, A. Maguire, L. Morelli, C. Stevens, S. Verdesca, S. Voitik, R. Rose
Mayo Clinic Comprehensive Cancer Center, Florida

57. Integrating Expertise: Forming a Unified Hybrid Clinical Trial Team for Cancer-Related Research
M. Wren, S. Voitik, A. Maguire, D. Harwood
Mayo Clinic Comprehensive Cancer Center, Florida

58. Enhanced Activation of Multicenter Investigator-Initiated Trials With Dedicated Multicenter Activation Team
C. Friedman, J. Walkley, M. Warren, K. Muenkel, J. Migliacci, M. Kehoe, A. Mayer, P. Nolan, C. Houston
Memorial Sloan Kettering Cancer Center

59. How Can We Improve Data Integrity in Risk-Based Monitoring? A Structured TSDV Strategy
S. Sanchez-Molero Perez, A. Granobles, K. Mantha-Thaler, K. Yataghene
Memorial Sloan Kettering Cancer Center

60. Development of a Screening Coordinator Dashboard to Optimize Clinical Trial Pre-Screening and Enhance Enrollment Strategies Across Multiple Disease Programs
A. Sansil, F. Bustamante, A. Aminpour, S. Fazilova, K. Sprenger, E. Cadena, P. Olaore, M. Davis, I. Krupitsky, P. Lewis, K. Namana, M. Ugrenovic-Petrovic, E. Royster, J. Lebsack, H. Soliman
Moffitt Cancer Center

61. Expansion of Clinical Trials to the Moffitt Ambulatory Centers
A. Richards, M. Ott, E. Royster, E. Cadena, P. Olaore, M. Colon Colon, T. Freeman, M. Grullon, M. Burton, C. Michel, E. Fussell, M. Ugrenovic-Petrovic, H. Soliman, J. Lebsack
Moffitt Cancer Center

62. Optimizing Clinical Trial Reporting: A Metrics-Driven Analysis of CTRP & ClinicalTrials.gov
J. Cardin, D. Castro, L. Fournier, M. Roberts
OHSU Knight Cancer Institute

63. Strategies for Increasing Accrual Utilizing Multi-Faceted Pre-Screening Methodologies and Systems
N. Ostrowsky-Fabisch, R. Kurz, B. Saraiya
Rutgers Cancer Institute

64. The Informed Advantage: Consent Support Hotline
D. O'Neill, C. Jerome, J. McGraw, A. Dudley, A. Gorman, B. Scruggs
Sidney Kimmel Comprehensive Cancer Center at Jefferson

65. Fast-Track Pilot Program
J. Quivers, E. Williams, A. Riley, Y. Pitts, D. Thomas, C. Farrell, D. Rodriguez, V. Poleboina, S. Issac, J. Kern, L. Thai, S. Holdridge, T. Zhang, A. Rahimi
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

66. Driving the Efficient Development of Investigator-Initiated Trials Through Streamlined Processes and Faculty Engagement
N. Odunewu, E. Andreae, D. Kazandjian
Sylvester Comprehensive Cancer Center, University of Miami Health System

2025 Abstracts

67. Implementing Focused Quality Spot Checks to Enhance Data Quality and Internal SOP Compliance
R. Fouts, K. Dodds, J. Zvosec
The Ohio State University Comprehensive Cancer Center – The James

68. Creating a Specialized Regulatory Office
B. Denton, J. Solsky, E. McPeak, R. Shroff
The University of Arizona Cancer Center

69. Creation and Structure of an Investigator-Initiated Trials (IIT) Support Group to Assist Investigators in the IIT Development Process
R. Jarrett, M. Chu, A. Scott, R. Shroff
The University of Arizona Cancer Center

70. Propelling NCTN Study Compliance and Excellence: Introducing the NCTN Monitor Role
L. Ramos-Barrera, D. Peterson, M. Srivastava, N. Fleming, A. Krone
The University of Arizona Cancer Center

71. Enhancing Clinical Trial Success: The Benefits of Mock Runs in Trial Preparation and Execution
M. Maideen, A. Kaur, E. Shah
The University of Chicago Medicine Comprehensive Cancer Center

72. Creation and Implementation of Automated Report Sections for Streamlined IND Annual Reports
B. Ostrander, I. Nzuki, N. Karanja-Meek, K. Mulvaney
The University of Kansas Cancer Center

73. Cross-System Data Validation: Ensuring Consistency and Compliance With SQL Joins
D. Keusch, E. Eells, I. Nzuki, N. Karanja-Meek, M. Willer
The University of Kansas Cancer Center

74. So You Want to Build A Radiopharmaceutical Program? Lessons Learned
K. Schwensen, E. Winters, S. Annis
The University of Kansas Cancer Center

75. Taking Preemptive Action With Monthly Compliance Newsletters for Oncology Clinical Trials
J. Fang, J. McAdams, M. Gawliu, K. Kelley
UCSF Helen Diller Family Comprehensive Cancer Center

76. Optimizing Data Quality and Trend Tracking in Oncology Clinical Trials: IIT Data Dashboard
S. Rachuri, K. Douglas, L. Barry, J. Tewell, A. Patwardhan, R. Johnson, T. Carroll, R. Gattas, K. Kennedy, S. Balu, K. Morrison, E. Crecelius
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

77. Fast-Tracking Cancer Research: Optimizing Study Startup for Accelerated Trial Activation at UFHCC
K. Calbart, E. Monari, A. Kukulka, A. Anderson, N. McGrew, A. Ivey, P. Crispen, T. George, C. Cline
University of Florida Health Cancer Center

78. Implementation of Protocol Amendment Project Manager to Improve Protocol Implementation Timeline
A. Kukulka, K. Calbart, D. Veal, T. George, P. Crispen, C. Cline, E. Monari, A. Anderson, A. Ivey, L. Brown
University of Florida Health Cancer Center

79. Assess the Impact of Repeat Imaging and Assessments on Patient Enrollment in Oncology Clinical Trials
S. Shivpura Ramesh, A. Guzman, R. Nguyen, A. Aseem
University of Illinois Cancer Center

80. Implementation of Advarra eReg
J. Humfleet, E. Enselman, C. Leister, D. Bashllari
University of Michigan Rogel Cancer Center

81. Cancer Center CTO Routine Care Labs, Imaging, & Provider Visits at Locations More Convenient for Trial Participants
S. Zindars, N. Johnson, A. Eve, E. Polak, L. Heldt, C. Dwight, E Lynch
Medical College of Wisconsin Cancer Center

82. PI Supervision and Oversight: Multi-Center IITs
A. Shah, K. Brown, N. Shuman, B. Halmos
Montefiore Einstein Comprehensive Cancer Center

83. Expanding Decentralized Clinical Trial Options at the UCSF Helen Diller Family Cancer Center
A. Yost, W. Truong, A. Skafel, M. Feng, R. Aggarwal
UCSF Helen Diller Family Comprehensive Cancer Center

Community Outreach and Engagement & Health Equity

84. Clinical Research Diversity: Engagement and Enrollment Model
S. Mekonnen, M. Martinez, L. Ferrara, K. Forrester, M. Lonhart, D. Potts, T. Howard
OHSU Knight Cancer Institute

85. Implementation of a Patient Navigation Program to Increase Representative Enrollment in Cancer Clinical Trials
S. Makhnoon, F. Robles, J. Lee, D. Grant, M. Rojas, L. Thomas, A. Gao, C. Pezzia, N. Sadeghi, S. Zhang, T. Hulsey, R. Renn, V. Eluri, E. Williams, H. Kitzman, D. Gerber
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

86. Hybrid Operations to Promote Equity (HOPE) - Bringing Trials Closer to Patients
K. Morrison, J. Potter, E. Moore, S. Wheeler, B. Martin, C. Lee
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

87. Determining Community Experiences With and Interest in Oncology Clinical Trials Through Surveys With John Theurer Cancer Center Patient Populations and Non-Patient Populations in Northern New Jersey
K. Suqui, S. Marks, E. Shoulders, E. Richards, L. Carter-Bawa
Georgetown Lombardi Comprehensive Cancer Center

2025 Abstracts

88. Enhancing Clinical Trial Education and Outreach in the Mountain West: A Collaborative Approach by Huntsman Cancer Institute
J. Moehle, C. Gavile, G. Nachaegari, A. Foust, J. Yancy, D. Branson, C. Moss, M. Vehar, E. Bade, A. Finch, L. Lujan, H. Soares, R. Ceballos, T. Werner
Huntsman Cancer Institute at the University of Utah

89. Fostering Equity in Oncology Trials: A Multi-Campus Approach to Increasing Clinical Trial Participation
B. Bodin, T. Imtiaz, A. Joshi, J. Mehnert, D. Marks, B. Pothuri
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

90. Interventions to Increase GYN Trial Enrollment Through Strategic Sequencing of Trials and Optimized Partnerships with Community Hospitals
M. Armstrong, E. Waalkes, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

91. TrialConnect Initiative - Increasing Catchment Area for Clinical Trials Enrollment in Long Island and Queens
T. Imtiaz, D. Marks, A. Joshi, E. Aviki, R. Nelson, M. Salcedo, J. Mehnert, B. Pothuri
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

92. Community Recruitment Process for Cancer Trials: Expanding Access to Underrepresented Populations
S. Casanova Leyva, L. Pacheco-Spann, S. Confiado, K. Barbel-Johnson
Mayo Clinic Comprehensive Cancer Center, Florida

93. Illusion of Inclusion: Exploring Asexual Exclusion in Research and Training
M. DiMeglio, E. Drake, E. Lemin, A. Lopez
Sidney Kimmel Comprehensive Cancer Center at Jefferson

94. Patient-Centric and Community-Engaged Development of a Clinical Trial Summary Tool to Enhance Clinical Trial Communication and Access
F. Robles, T. Wang, E. Ruiz, Z. Griggs, B. Williams, E. Williams, Q. Qin, T. Zhang, H. Kitzman, C. Jiang
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

95. Scaling Up Research at Eskenazi: A Strategic Plan for Growth and Inclusion
L. Sego, L. Haney, A. Al-Hader
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Cross-Cutting Innovation and Collaboration

96. Clinical Trials in the Community: Building Patient Trust and Improving Access
E. Meisler, K. Brenner, A. Frank, W. Hildebrandt, L. Mirossay, E. Slanoc
Cleveland Clinic Cancer Center Foundation; Cleveland Clinic Foundation

97. Recognizing Revenue in a Matrix Cancer Center Clinical Trials Office: Functionality, Issues, and How It Can Be Improved
Z. Crawford, M. Mavredes, S. Levy
Georgetown Lombardi Comprehensive Cancer Center

98. Research Trials Review Committee: Supporting Non-Treatment Trials, a New Approach
J. Moehle, M. Loveless, T. Warner, D. Sborov, N. Agarwal, T. Onega, B. Daniels, D. Ma, S. Schlater, K. Thorne, E. Olsen, A. Lam, T. Hurty
Huntsman Cancer Institute at the University of Utah

99. Population Engagement and Research Laboratory (PEARL)
N. Francis, N. Naas, K. Moffett, T. Hoffert, A. Hoehn, T. Crocker, J. McCoy, A. Rodriguez, C. Daise-Wilson
Moffitt Cancer Center

100. Creating a Clinical Trial Referral Tool to Assist in Increasing Accruals Across a Multi-Site Cancer Center
K. Hearne, L. Varela, M. Maroccia, A. Mancini, G. DeGennaro, S. Torrents, A. Alencar
Sylvester Comprehensive Cancer Center, University of Miami Health System

101. Decentralizing Oncology Treatment Trials at Local Safety Net Hospital to Increase Under-Represented Minority (URM) Enrollment With Hub and Spoke Model
K. Kipping-Johnson, R. Szmulewitz, S. Chmura, M. Kozloff, K. Kruczek, I. Abraham, A. Tolentino, L. Wall, M. Marriott, J. Wallace
The University of Chicago Medicine Comprehensive Cancer Center

102. Measuring the Impact of Multiple Strategies to Increase Enrollment in Molecular Targeted Trials
L. Wall, V. Seseri, K. Kipping-Johnson, K. Cabrera, A. Larkin, S. Moellering
The University of Chicago Medicine Comprehensive Cancer Center

103. Breaking Boundaries: Enhancing Infusion Chair Utilization in Phase I Research
K. Pavlik, C. Wiess, C. Servodidio, S. Marshall-Wray, M. Fradkin, T. Carafeno
Yale Cancer Center, Yale School of Medicine

104. Advanced Project Manager- Getting Projects Moving
L. Rohn, M. Contreraz
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

105. Bridging Units, Building Empathy: The Power of a Day-in-the-Life Program and Shadowing in the Clinical Trials Office (CTO)
E. Waalkes, E. O'Donovan, M. Dureja, J. Alonso, B. Bodin, A. Joshi, J. Mehnert, B. Pothuri
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

106. Integration of Electronic Health Record (EHR) Systems With Electronic Data Capture (EDC)
A. Almazar, J. Lengfellner, L. Andrews, M. Bush, A. Fritsche
Mayo Clinic Comprehensive Cancer Center

2025 Abstracts

107. There's No Place Like Home
S. Confiado, K. Lopez, D. Chapin, A. Baskin, J. Vines, D. Glaser-Boivin, M. Szewczynski, S. Verdesca, R. Dronca
Mayo Clinic Comprehensive Cancer Center, Florida

108. Breaking Barriers: A Digital Tool for Expanding Clinical Trial Referrals for Hematology Patients
F. Bustamante, D. Sallman, J. Edelman, J. Adkins, G. Bryant, M. Ugrenovic-Petrovic
Moffitt Cancer Center

109. Clinical Research Inpatient Nursing Optimization – Post Trial Activation
J. Macaisa, A. Couch, M. Williams, M. Ugrenovic-Petrovic, A. Shrewsbury, L. Burger, B. Mack, J. Edelman, K. Foster, A. Spanolios, E. Royster
Moffitt Cancer Center

110. OnCore Financials and High Per-Patient Revenue Clinical Trials – Impact of Discharged Not Final Billed (DNFB)
A. Shrewsbury, M. Ugrenovic-Petrovic, D. Gosnell, I. Krupitsky, M. Davis, L. Ansley, J. Lebsack, C. Cifuentes, M. Brechbuhler, A. Talford
Moffitt Cancer Center

111. Revolutionizing the Clinical Research Revenue Cycle with G.E.M.S.: A Cross-Functional Tool Mapping Hospital and Research Chargemasters to Enhance Workflows With Automation
K. Hulse, D. Gosnell, I. Krupitsky, M. Brechbuhler, H. Anderson, M. Cox, J. Toombs, L. Dieguez, M. Ugrenovic-Petrovic, E. Royster, B. Mack, M. Cochran
Moffitt Cancer Center

112. Charting a New Course: Operationalizing Non-Oncology Cellular Therapy Trials
N. Muhammad, L. Reardon, S. Marsh, J. Morrison, L. Wilkerson, R. Brown
Sidney Kimmel Comprehensive Cancer Center at Jefferson

113. Increasing Clinical Trial Efficiency and Visibility Through an Internal Data Analytics Platform
K. Sinclair, T. DuBois, C. McNair
Sidney Kimmel Comprehensive Cancer Center at Jefferson

114. Streamlining Cancer Research: A Centralized Hub for Clinical Trials, Professional Development, and Staff Resources
B. Scruggs, N. Hartman, M. Sherman, K. Herman
Sidney Kimmel Comprehensive Cancer Center at Jefferson

115. Streamlining PRMS Microprocesses: A Collaborative Guide to Reduce Study Activation Timelines and Increase Accrual by Prioritizing Review Assessments Through Continual Monitoring
T. Levine, A. Riley, C. Escalante, T. Jefferson, E. Williams, J. Quivers, K. Courtney
Simmons Comprehensive Cancer Center, UT Southwestern Medical Center

116. Automating Data and Safety Monitoring Committee (DSMC) Communication: Streamlining Operations and Enhancing Data-Driven Decision-Making
A. Khan, A. Nika
Stanford Cancer Institute

117. How to Partner With the Veterans' Administration on Early Phase Clinical Trials
J. Baranda, C. Huang, W. Sun, G. Doolittle, N. Streeter, T. Lin, J. Fields-Meehan, R. Sharma, J. Gouda, S. Kambhampati, H. Krebill, S. Gore, P. Ivy, P. LoRusso, R. Jensen
The University of Kansas Cancer Center

118. Non-Malignant Cell Therapy Integration and Collaboration With Cancer Research at an Academic Medical Center
E. Winters, J. McGuirk, Z. Mamoudjafari, B. Turk
The University of Kansas Cancer Center

119. Enhancing Clinical Trial Access and Enrollment for Acute Leukemia Patients: An Innovative Single-Institution Experience of the Leukemia Expanded Access Program (LEAP)
A. McKinney, R. Tolley, J. Zeidner
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

120. Academic Collaborations for DSMB Oversight of High Risk IITs
N. McGrew, L. Maurer, P. Deleyrolle, T. George, T. Werner, E. Monari, K. Thorne
University of Florida Health Cancer Center

121. Papers & Spreadsheets & Calls, Oh My!: Where Sample Data Falls Through the Cracks
J. Voyten, A. Yant, M. Horak
UPMC Hillman Cancer Center

Emerging Technology

122. Scaling EHR-To-EDC Across the Clinical Research Portfolio: Lessons From MSK
A. Patruno, M. Panzarella, S. O'Shea, C. Thomas, M. Silverman, R. Panchal, J. Lengfellner, P. Sabbatini
Memorial Sloan Kettering Cancer Center

Prioritization and Scientific Review

123. Revamping Clinical Trials Accrual Monitoring
B. Bachman, B. Stevens, A. Al Shammaa, K. Van Abel
Mayo Clinic Comprehensive Cancer Center

124. PRMC Accrual Monitoring: Let's Get Real
R. Dampman, S. Osipowicz, J. Johnson, J. Curry
Sidney Kimmel Comprehensive Cancer Center at Jefferson

125. Implementing a Non-Therapeutic Feasibility Committee at a Comprehensive Cancer Center
N. Naas, A. Hoehn
Moffitt Cancer Center

126. Methods and Workflows to Increase Study Accruals
S. Hughes, M. Rastogi, D. Avins, N. Shakhnazaryan, L. Kody, L. Trihy, M. VanderZanden
UCSF Helen Diller Family Comprehensive Cancer Center

2025 Abstracts

127. Implementation of the Protocol Review Committee's Low Accrual Guidance
C. Narag, A. Thomas, J. Huamani-Bundy, A. Weiner, A. Beaven
UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Training, Career Development, and Staff Retention

128. Learning the Research Process: Clinical Education for Management of Oncology Research Trials
B. Elliott, M. Firman, E. Fawley, J. Samsa, S. Braley
Cleveland Clinic Cancer Center

129. Cultivating Gratitude: A Culture of Appreciation
F. Kerr
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

130. Creating a 'Take' on Continuing Education for Clinical Study Team Staff: Micro-Training Flyers
K. Croghan, G. Boe, A. Nascene, S. Hildebrandt, A. Fritsche
Mayo Clinic Comprehensive Cancer Center

131. Cancer Clinical Studies Unit Hiring Efficiencies and Leadership Impact
A. Young, D. Haley, D. Chapin, D. Giovannagelo, S. Verdesca, S. Confiado
Mayo Clinic Comprehensive Cancer Center, Florida

132. Automated Quantification of a Research Data Coordinator's Workload for Staff Retention and Staffing Planning
D. Goodridge, M. Ott, C. Machado, I. Krupitsky, E. Royster, M. Ugrenovic-Petrovic, J. Lebsack
Moffitt Cancer Center

133. Increasing Retention of Clinical Research Assistants
K. Humphries, R. Link, A. Campbell
The Ohio State University Comprehensive Cancer Center – The James

134. Enhancing Workforce Readiness and Growth: A Comprehensive Orientation and Professional Development Strategy at The University of Kansas Cancer Center Clinical Trials Office
K. Deculus, R. Lewis, J. Pitzen, L. Ruelas
The University of Kansas Cancer Center

135. Educating the Next Generation of PIs: CTO Fellows Rotation
N. Kurtzweil, I. Monroe, P. Rose
University of Cincinnati Cancer Center

136. Development of Monitoring Tools and Interventions to Increase Staff and Faculty Consent Success Rates
M. Russell, D. Kitterman
University of Illinois Cancer Center

137. Restructuring Team Meetings to Reduce Stress, Improve Communication and Tackle Workload Burden
J. Laeng
Cleveland Clinic Cancer Center

138. From Data to Decisions: Enhancing Data-Driven Decision Making and Persuasive Communication Skills in Clinical Trials Managers
A. Rice-Warren, S. Belanger, C. Fournier
Duke Cancer Institute

139. Optimizing Workload Management in Phase I Oncology Clinical Research Through Novel Oncology - Phase-I Acuity Scoring System (O-PASS)
S. Fabrie, M. Dort, W. Paez, T. Kochukoshy, A. Olszanski
Fox Chase Cancer Center, Temple Health

140. Learning Evaluation & Advancement Plan (LEAP)
H. Willis, F. Kerr, S. Asche
Indiana University Melvin and Bren Simon Comprehensive Cancer Center

141. Cancer Protocol Review and Monitoring Committee (PRMC) Mentorship Program
B. Stevens, B. Bachman, K. Van Abel, B. Siontis
Mayo Clinic Comprehensive Cancer Center

142. From Mentorship to Leadership: Cultivating Authentic Leaders for Internal Promotions and Staff Retention in the Mayo Clinic in Florida Protocol Development Unit – A Comprehensive Approach to Empowering Front-Line Staff
A. Maguire, S. Voitik, D. Harwood, L. Hanson, M. Althuis Wrenn
Mayo Clinic Comprehensive Cancer Center, Florida

143. A Focus on Culture in Response to Rapid Growth: Moffitt Cancer Center's Non-Therapeutic Research Office (NTRO)
L. Camperlengo
Moffitt Cancer Center

144. Bridging the Gap: Academic-Industry Partnership for Clinical Research Training
J. Germain, K. Moffett, N. Naas, S. Ahmed, T. Wells
Moffitt Cancer Center

145. Implementing Foundational Clinical Research Training in Initial Onboarding
D. Kreitner, J. Friedel, R. Lewis, K. Todd, S. Tabatabaei, T. Williams, N. Smeck, E. Solanki, M. Ferguson
OHSU Knight Cancer Institute

146. Initial Onboarding: Smartsheet Training Dashboard
D. Kreitner, J. Friedel, R. Lewis, C. Burgin
OHSU Knight Cancer Institute

2025 Abstracts

147. A Dedicated Curriculum to Develop Clinical Cancer Research Concepts: An R25 Supported, AACI Collaborative Effort
D. Owen, R. Wesolowski, A. McMahon, E. Klein, J. Hays, C. Verschraegen
The Ohio State University Comprehensive Cancer Center – The James

148. Addressing the Urgent Demand for Clinical Research Professionals Through a Novel Training Initiative
A. Ward, C. Frost-Brewer, L. Wall
The University of Chicago Medicine Comprehensive Cancer Center

149. AMPLIFIED: Enhancing Workforce Readiness in Research Through Professional Development
R. Lewis, S. Stites, A. Carr
The University of Kansas Cancer Center

150. Building Clinical Research Coordinator (CRC) Excellence: Insights From Our Clinical Research Assistant (CRA) to Clinical Research Coordinator (CRC) Pipeline (Where We Are Now)
S. Annis, J. De Jong, J. Smith
The University of Kansas Cancer Center

151. Clearly Lighting the Way: Illuminating the Pathway to Careers in Clinical Research Coordination in the University of Kansas Cancer Center's Clinical Trial Office (KUCC-CTO) with C-CLEAR the Careers in CLinical ResEARch Summer Experience
J. Hines, R. Lewis, J. Pitzen, K. Deculus, L. Ruelas
The University of Kansas Cancer Center

152. Developing a Core Oncology Curriculum for Research Personnel
G. Lacatus, J. Appelt, J. Molina, N. Johal, A. Malko, J. Warbrick, R. McKay, R. Eskander, J. Nancarrow
UC San Diego Moores Cancer Center

153. Investment in People: Creating a Positive Culture in the MCC CTO
N. Johal, J. Tull, A. Malko, J. Molina, J. Appelt, J. Warbrick, M. Suggs, R. McKay, R. Eskander
UC San Diego Moores Cancer Center

154. New Manager Training Refresh
M. VanderZanden, A. Oglesby, E. Nurminen
UCSF Helen Diller Family Comprehensive Cancer Center

155. Using Measured Learning Outcomes to Ensure Efficacy in Instructor Led Training
A. Poore, V. Jennrich, K. Hogan
University of Colorado Cancer Center

156. Centralized Knowledge Hub: Streamlining Access to Clinical Research Resources on SharePoint
K. French, D. DeGray
Wilmot Cancer Institute, UR Medicine

157. Drip-Feed Learning: Spaced MicroTraining in Clinical Research Professional Development
J. Thomas, A. Kukulka, T. George, E. Monari, P. Crispen, C. Cline
University of Florida Health Cancer Center

AACI CRI Supporters

AACI gratefully acknowledges support from the following:

Premier Supporter

MERCK
INVENTING FOR LIFE

NOVARTIS

Champion Supporter

ADVARRA

Bristol Myers Squibb™

HURON

Veeva

verily

Additional Support

BeOne

Paradigm Health

TRIOMICS

As of June 16, 2025

AACI CRI Exhibitors

AACI gratefully acknowledges support from the following:

As of June 16, 2025

AACI CRI Exhibitors

Actalent

Actalent is a global leader in engineering and sciences services and talent solutions. We help visionary companies advance their engineering and science initiatives through access to specialized experts who drive scale, innovation, and speed to market. With a network of almost 30,000 consultants and more than 4,500 clients across the U.S., Canada, Asia, and Europe, Actalent serves many of the Fortune 500.

Advarra

Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, site and sponsor technology, and clinical trial experience software, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions enable the collaboration, transparency, and speed to optimize trial operations, ensure patient safety and engagement, and reimagine clinical research while improving compliance.

AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. Please follow the company on social media: **@AstraZeneca**.

Caris Life Sciences

Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company's suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. Follow us on X/Twitter: **@CarisLS**.

Florence Healthcare

Florence Healthcare is a leading provider of Site Enablement solutions that streamline clinical research operations and improve collaboration among research sites, sponsors, and CROs. With a focus on driving innovation and enhancing the trial site experience through site enablement, Florence Healthcare is committed to closing the cure acceleration gap and revolutionizing the clinical trial industry.

AACI CRI Exhibitors

Huron

Huron's cancer center team is composed of leaders with 20-plus years of frontline experience in academic-based cancer centers. They rely on their firsthand knowledge of best practices to help improve your center's performance across multiple dimensions, tailoring approaches and solutions to your center's goals, issues and organizational environment. Our team has worked with over 75 aspiring and established cancer centers, notably assisting institutions in renewing or obtaining their first National Cancer Institute (NCI) designation award and designing a statewide, multi-institutional organizational structure for conducting clinical trials. We have extensive experience in the clinical research, clinical trials and biotechnology spaces, spurring innovation and advancing knowledge.

IgniteData

IgniteData's market-leading data transfer technology, Archer, is transforming the future of clinical trials, bringing all the benefits of fast, accurate EHR-to-EDC data transfer to sites and sponsors alike.

- Validated and in use by sites and sponsors internationally
- Enterprise-level eSource-to-Sponsor data transfer platform designed for research sites
- System-agnostic - integrates seamlessly with all major EHRs and research systems
- Scalable by design - ideal for multiple studies and multiple sites.
- Purpose-built mapping engine matches and normalises data, providing export-ready data without the effort
- Easy-to-use and loved by researchers: the clinician is always in control
- Rapid eSource-to-Sponsor data transfer – up to 96% faster than manual methods
- Can map and transfer 100% of Vital Signs and Labs data
- Significantly reduces Source Data Verification (SDV) and query resolution time
- Hassle-free implementation and streamlined licensing process

Medidata

The Medidata Platform connects patients, sites, sponsors, and CROs in a unified, secure, and scalable cloud environment to bring life-changing treatments to those who need them most.

- Use a common user experience across all your trial tasks
- Centrally manage your clinical and operational data
- Easily integrate with your existing systems
- Accelerate your workflows with automation and AI

nCartes

nCartes is a transformational EHR-to-EDC cloud software platform. nCartes enables clinical research sites and sponsors to harness electronic health record systems (EHRs) to automate data capture for clinical trials, patient registries, cell manufacturing and more. nCartes sites report time and cost reductions in study data entry of as much as 50% while also materially reducing data entry mistakes and related work associated with source data verification. nCartes is a proud collaborator with the **SWOG Cancer Research Network** whose sites have also experienced considerable success with nCartes on SWOG trials. To learn more, please stop by the nCartes exhibit or contact **info@ncoup.com**.

Veeva

Veeva is the global leader in cloud software for the life sciences industry, serving more than 1,000 biopharma companies—including 18 of the top 20 pharmas—7,000 clinical research sites, and 25,000 patients. As a Public Benefit Corporation, Veeva aims to reduce the technology burden among sites and make clinical trials more accessible to patients.

Verily

Verily is a subsidiary of Alphabet that is using a data-driven, people-first approach to change the way people manage their health and the way healthcare is delivered. Launched from X in 2015, Verily's purpose is to bring the promise of precision health to everyone, every day. Verily is focused on generating and activating data from a wide variety of sources, including clinical, social, behavioral and the real world, to arrive at the best solutions for a person based on a comprehensive view of the evidence. Verily uses its recognized expertise and capabilities in technology, data science and healthcare to enable the entire healthcare ecosystem to drive better health outcomes.

Our solutions bring together evidence generation, care delivery and care management in a connected and reinforcing ecosystem built to advance precision health, connecting research participants with studies and offering tools to improve clinical research. This includes SignalPath, the only state-of-the-art clinical trial management system (CTMS) with proprietary protocol digitization technology that was built by researchers, for researchers, to help dramatically improve the ease, quality, efficiency and profitability of trial execution.

AACI CRI Exhibitors

WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives.

Yunu

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu's aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management.

As of June 16, 2025

STATE OF CANCER CARE IN AMERICA™

A healthy workforce is essential for delivering high-quality cancer care, but more and more oncologists are experiencing burnout.

An ASCO survey of U.S.-based oncologists found a significant increase in burnout among oncologists, rising from 45% in 2013 to 59% in 2023.

75% of oncologists who reported burnout said they would reduce clinical hours in the next 12 months.

Younger oncologists report higher rates of burnout than their older counterparts:
64% among those under age 50
51% among those 50 years and older.

To ensure high-quality cancer care, it's vital to improve the well-being of clinicians and build a sustainable oncology workforce.

Learn more about ASCO's State of Cancer Care in America publications.

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY
KNOWLEDGE CONQUERS CANCER

IgniteData

EHR to EDC —Reimagined for Research Sites

Faster Data. Fewer Errors. No Extra Cost.

The Problem: Manual Data Entry Slows Trials

Research sites struggle with:

- **High error rates** and compliance risks
- **Time-consuming transcription** and verification
- **CRC turnover** due to manual workload
- **Limited resources,** increasing operational strain

The Solution: IgniteData Archer

Archer automates **EHR-to-EDC data transfer**, significantly reducing manual entry and ensuring **real-time, accurate data capture**.

Why Research Sites Choose Archer

- **70% time savings,** freeing CRCs for patient care
- **99.9% accuracy,** reducing queries and SDV costs
- **Zero cost to sites,** fully covered by sponsors
- **Regulatory compliance,** ensuring secure, audit-ready data
- **Improved retention,** reducing CRC burnout

Proven Across Leading Research Institutions

- Trusted by **MD Anderson, Mayo Clinic, MSK, City of Hope,** and more
- Integrates seamlessly with **Epic, Cerner, and other major EHRs**
- **87% fewer queries,** accelerating trials and strengthening sponsor partnerships

More Trials. More Revenue. Less Work.

Learn more at www.ignitedata.com Contact chin@ignitedata.com for a demo

yunu

Let imaging become your advantage

Yunu eliminates trial imaging error rates as high as 50%

Yunu's clinical trial imaging platform drives efficient and harmonized workflows, creates a collaborative work environment across stakeholders, and ensures assessments are accurate and complete before every patient visit.

Yunu customers can:

- Reduce imaging data error rates as high as 50% down to < 1%
- Increase trial volumes by an average of 40% in the first year.
- Accelerate trial timelines by 10% or more.

yunu.io

info@yunu.io

A smarter approach to imaging

See everything
Real-time data & always audit-ready

Collaborate freely
Connect stakeholders & access on-demand readers

Move faster
30-minute study starts & no change orders

Get it right
Ensure accuracy from initial scan to sponsor data systems